Patents Issued in March 13, 2018
-
Patent number: 9913887Abstract: The present invention encompasses methods and compositions for Ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for Ureaplasma, including DNA vaccines. In certain embodiments, the invention regards vaccines directed towards the multiple-banded antigen(s) of Ureaplasma.Type: GrantFiled: December 14, 2015Date of Patent: March 13, 2018Assignee: Baylor College of MedicineInventors: Leonard Weisman, Lingkun Kong
-
Patent number: 9913888Abstract: The present document discloses a new species of Bizionia, herein denoted Bizionia piscinecroseptica and a reference strain of this bacterium denoted Bizionia sp. 130524K2F7 which has been deposited at the National Collection of Industrial and Marine Bacteria and has been assigned accession number NCIMB 42183. Further disclosed is the medical use of bacteria of the genus Bizionia for vaccinating fish against a new disease identified and herein denoted bizioniosis.Type: GrantFiled: November 13, 2014Date of Patent: March 13, 2018Assignee: NORGES MILJØ- OG BIOVITENSKAPELIGE UNIVERSITET (NMBU)Inventor: Henning Sørum
-
Patent number: 9913889Abstract: The present application provides methods of stimulating an immune response, such as a protective immune response against Treponema pallidum infection. Such methods utilize fragments of the Tp0751 protein (such as any of SEQ ID NOs: 3-10, those N-terminally truncated from amino acids 1 through 77, 1 through 114, or anywhere in between, e.g., those that start at any amino acid from 78 to 115). In some examples, a Tp0751 protein fragment has a mutated HEXXH site (HEXXH is the wild-type sequence). Also provided are the isolated soluble Tp0751 protein fragments that include a wild-type or mutated HEXXH site, as well as nucleic acids encoding such proteins and kits that include such proteins.Type: GrantFiled: January 12, 2016Date of Patent: March 13, 2018Assignee: UVic Industry Partnerships Inc.Inventors: Caroline E. Cameron, Rebecca M. Hof, Simon A. Houston, Martin John Boulanger
-
Patent number: 9913890Abstract: Compositions effective for treating or preventing an anthrax infection in a subject in need thereof and recombinant proteins included in the compositions are provided. Methods for producing recombinant proteins in plants are described. Transgenic plants engineered to produce recombinant proteins as well as genetic constructs comprising nucleic acids encoding recombinant proteins thereof are also described. Methods of protecting subjects against anthrax infection with plant-derived compositions are provided.Type: GrantFiled: June 20, 2013Date of Patent: March 13, 2018Assignee: PHARMA GREEN LLCInventors: Vyacheslav Andrianov, Maxim Golovkin
-
Patent number: 9913891Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.Type: GrantFiled: November 16, 2016Date of Patent: March 13, 2018Assignee: MERIAL INC.Inventors: Jean-Christophe Audonnet, Frédéric Reynard, Natalia Bomchil, Cécile Sigoillot-Claude
-
Patent number: 9913892Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: October 6, 2014Date of Patent: March 13, 2018Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
-
Patent number: 9913893Abstract: Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.Type: GrantFiled: February 16, 2015Date of Patent: March 13, 2018Assignee: The Board of Trustees of the University of ArkansasInventors: Luc Berghman, Walter Bottje, Billy Hargis, Sherryll Layton
-
Patent number: 9913894Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.Type: GrantFiled: July 13, 2015Date of Patent: March 13, 2018Assignee: MedImmune, LLCInventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
-
Patent number: 9913895Abstract: The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as HIV, SIV, or FIV. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses. In one embodiment, the epitope is one that is conserved between HIV and SIV, or between HIV and FIV. In another embodiment, the epitope is one that is conserved between HIV, SIV, and FIV.Type: GrantFiled: February 9, 2015Date of Patent: March 13, 2018Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Janet K. Yamamoto
-
Patent number: 9913896Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.Type: GrantFiled: December 14, 2016Date of Patent: March 13, 2018Assignee: MERIAL, INC.Inventor: Francois Xavier Le Gros
-
Patent number: 9913898Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.Type: GrantFiled: July 29, 2016Date of Patent: March 13, 2018Assignee: Valneva Austria GmbHInventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
-
Patent number: 9913899Abstract: Identification of candidates for treatment and treatment of subjects experiencing cerebral ischemia wherein the treatment employs a thrombolytic or thrombectomy agent and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are determined by testing the blood of a patient for total S-100B or for S-100BB as a marker of blood brain barrier integrity.Type: GrantFiled: March 13, 2015Date of Patent: March 13, 2018Assignee: Shimojani, LLCInventors: Lawrence M. Kauvar, Damir Janigro
-
Patent number: 9913900Abstract: The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof.Type: GrantFiled: April 21, 2017Date of Patent: March 13, 2018Assignees: AMGEN INC., THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Hua Zhu Ke, Min Liu, William V. Giannobile
-
Patent number: 9913901Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.Type: GrantFiled: December 3, 2013Date of Patent: March 13, 2018Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Victor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
-
Patent number: 9913902Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: September 28, 2017Date of Patent: March 13, 2018Assignee: ABBVIE BIOTECHNOLOGY LTD.Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 9913903Abstract: Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.Type: GrantFiled: May 5, 2016Date of Patent: March 13, 2018Assignee: Grifols Worldwide Operations LimitedInventors: Thomas Barnett, David A. Ross
-
Patent number: 9913904Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.Type: GrantFiled: February 15, 2017Date of Patent: March 13, 2018Assignee: IGNOVA GMBHInventors: Jan Wesjohann, Günter Sprotte, Ana Maria Waaga-Gasser
-
Patent number: 9913905Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.Type: GrantFiled: September 11, 2014Date of Patent: March 13, 2018Assignee: EAGLE BIOLOGICS, INC.Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
-
Patent number: 9913906Abstract: An embodiment of the present disclosure provides a composition that comprises hyaluronic acid, or its salt or derivative thereof, and an antimicrobial agent, such as zinc citrate, that does not degrade the hyaluronic acid molecule.Type: GrantFiled: January 14, 2016Date of Patent: March 13, 2018Inventor: Karen K. Brown
-
Patent number: 9913907Abstract: The present invention provides a composition for suppressing the expression of a KRAS gene, comprising a lipid particle containing, as a drug, a double-stranded nucleic acid having an antisense strand having a sequence of bases complementary to the sequence of at least 19 continuous bases of any one KRAS gene's mRNA of sequence Nos. 1 to 3; and a cationic lipid represented by the following formula (I): wherein R1 and R2, which are the same or different, are each linear or branched alkyl, alkenyl or alkynyl having a carbon number of from 12 to 24; L1 and L2, which are the same or different, are each —CO—O— or —O—CO—; a and b, which are the same or different, are each 1 to 3; and R3 is a hydrogen atom, alkyl having a carbon number of from 1 to 6, or alkenyl having a carbon number of from 3 to 6, and the like.Type: GrantFiled: July 16, 2013Date of Patent: March 13, 2018Assignees: KYOWA HAKKO KIRIN CO., LTD., DICERNA PHARMACEUTICALS, INC.Inventors: Tomoyuki Naoi, Takeshi Kuboyama, Junichi Enokizono, Toshihiko Ishii, Akihiro Tokunaga, Kentarou Hatanaka
-
Patent number: 9913908Abstract: The present disclosure refers to transdermal pharmaceutical bases that include a synergistic combination of a silicone base with a natural permeation enhancement composition (NPE). Further, these transdermal pharmaceutical bases are proposed to treat ear diseases in mammals. The silicone base includes silicone, pracaxi oil, and seje oil. Additionally, the NPE composition includes one or more phospholipids, one or more oils rich in essential fatty acids, behenic acid, and oleic acid, one or more skin lipids, and one or more butters rich in linoleic acid and linolenic acid. The synergistic combination of aforementioned natural components exhibit enhanced healing properties, thereby providing organic acids with antioxidant, antibacterial, and antifungal properties. The transdermal pharmaceutical bases are employed to increase the residence time of the medicament in the ear canal, and increase the penetration of the APIs into the affected area, thereby enhancing treatment effectiveness.Type: GrantFiled: August 20, 2015Date of Patent: March 13, 2018Assignee: Professional Compounding Centers of AmericaInventors: Chris V. Simmons, Daniel Banov
-
Patent number: 9913909Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.Type: GrantFiled: September 19, 2016Date of Patent: March 13, 2018Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger
-
Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Patent number: 9913910Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.Type: GrantFiled: September 19, 2016Date of Patent: March 13, 2018Assignee: Heron Therapeutics, Inc.Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller -
Patent number: 9913911Abstract: Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid and a linkage cleavable under reducing conditions, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems.Type: GrantFiled: December 7, 2016Date of Patent: March 13, 2018Assignee: California Institute of TechnologyInventors: Mark E. Davis, Akinleye Alabi
-
Patent number: 9913912Abstract: The present invention relates to carrier-linked prostanoid prodrugs of formula (I) Z1—(X0-L0-PG0)y (I), wherein Z1, X0, L0, PG0 and y have the meaning as indicated in the description and claims; pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. It further relates to their use as medicaments, especially for treating, controlling, delaying or preventing pulmonary arterial hypertension.Type: GrantFiled: December 6, 2013Date of Patent: March 13, 2018Assignee: Ascendis Pharma A/SInventors: Harald Rau, Guillaume Maitro, Ulrich Hersel, Oliver Keil, Thomas Wegge
-
Patent number: 9913913Abstract: A method for preparing a polymeric reagent is provided, which method includes the optional step of forming an N-hydroxysuccinimdyl ester derivative. Related methods, preparations, and so forth are also provided.Type: GrantFiled: June 16, 2016Date of Patent: March 13, 2018Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
-
Patent number: 9913914Abstract: The invention relates to novel polypeptides for transporting molecules across cell membranes and, particularly but not exclusively, biological membranes; a conjugate comprising at least one of said polypeptides and at least one selected molecule or agent co-joined or conjugated to said polypeptide for the purpose of transporting said molecule or agent across a cell membrane; a method of transporting at least one selected molecule or agent across a cell membrane involving the use of at least one of said polypeptides; a therapeutic comprising at least one of said conjugates; a combination therapeutic comprising at least one of said conjugates and at least one further therapeutic agent; a method of treatment involving the use of at least one of said conjugates or said therapeutics.Type: GrantFiled: October 9, 2014Date of Patent: March 13, 2018Assignee: CUPID PEPTIDE COMPANY LIMITEDInventor: William Jonathan Ryves
-
Patent number: 9913915Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.Type: GrantFiled: November 14, 2016Date of Patent: March 13, 2018Assignee: Ophidion Inc.Inventor: Andreas Walz
-
Patent number: 9913916Abstract: Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting.Type: GrantFiled: October 3, 2016Date of Patent: March 13, 2018Assignee: The University of North Carolina at Chapel HillInventors: Joseph M. DeSimone, Mathew Finniss, Mary Napier, Ashish Pandya, Matthew Parrott
-
Patent number: 9913917Abstract: The invention relates to highly fluorescent metal oxide nanoparticles to which biomolecules and other compounds can be chemically linked to form biocompatible, stable optical imaging agents for in vitro and in vivo applications. The fluorescent metal oxide nanoparticles may also be used for magnetic resonance imaging (MRI), thus providing a multi modality imaging agent.Type: GrantFiled: December 22, 2006Date of Patent: March 13, 2018Assignee: VisEn Medical, Inc.Inventors: Kevin Groves, Milind Rajopadhye
-
Patent number: 9913918Abstract: Recombinant host cells are provided. The cell genome contains heterologous gene expression cassettes capable of being expressed in the host cell, where the gene expression cassettes encode a nucleic acid sequence encompassing at least 80% of the full-length sequence of the mamAB operon, the mamGDFC operon, and the tmms6 operon of a magnetotactic alphaproteobacterium, respectively. The cells may further comprise gene expression cassettes capable of being expressed in the host cell, where the gene expression cassettes encode a nucleic acid sequence encompassing at least 80% of the full-length sequence of the mamXY operon and/or the feoABI operon of a magnetotactic alphaproteobacterium; where the recombinant host cell, upon expression of the gene expression cassettes in their entirety, is capable of producing magnetic nanoparticles. Preferably, the recombinant host cell is derived from Rhodospirillum rubrum. Methods of producing these recombinant host cells by genetic transposition are provided.Type: GrantFiled: June 10, 2014Date of Patent: March 13, 2018Assignee: UNIVERSITAT BAYREUTHInventors: Dirk Schüler, Isabel Kolinko
-
Patent number: 9913919Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.Type: GrantFiled: May 23, 2017Date of Patent: March 13, 2018Assignee: Lantheus Medical Imaging, Inc.Inventors: Simon P. Robinson, Robert W. Siegler, Nhung Tuyet Nguyen, David C. Onthank, Tarakeshwar Vishwanath Anklekar, Charles Chester Van Kirk
-
Patent number: 9913920Abstract: The disclosure relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.Type: GrantFiled: August 6, 2015Date of Patent: March 13, 2018Assignees: VIB VZW, Vrije Universiteit BrusselInventors: Kiavash Movahedi, Damya Laoui, Steve Schoonooghe, Geert Raes, Patrick De Baetselier, Jo Van Ginderachter, Nick Devoogdt, Tony Lahoutte
-
Patent number: 9913921Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds.Type: GrantFiled: May 7, 2012Date of Patent: March 13, 2018Assignee: TAGWORKS PHARMACEUTICALS B.V.Inventors: Marc Stefan Robillard, Johan Lub, Raffaella Rossin, Sandra Martina Van Ben Bosch, Ronny Mathieu Versteegen
-
Patent number: 9913922Abstract: A sterilizing component removal device which reduces a sterilizing component sprayed in a working chamber having an outlet includes a sprayer which supplies, in an atomized manner, a liquid different from the sterilizing component into the working chamber.Type: GrantFiled: March 30, 2015Date of Patent: March 13, 2018Assignees: PANASONIC CORPORATION, Panasonic Healthcare Co., Ltd.Inventors: Hiroko Murayama, Tatsushi Ohyama, Masahiro Iseki, Hironobu Sekine, Koichi Kobayashi, Hiroshi Yamamoto
-
Patent number: 9913923Abstract: A system for decontaminating an enclosed area includes a reservoir containing a disinfectant solution therein. One or more pumps are in fluid communication with the reservoir. One or more ports are operatively connected to the reservoir or operatively connected to an enclosed area to be decontaminated or operatively connected to the reservoir and to an enclosed area to be decontaminated. One or more connector assemblies are removably attachable to the one or more ports to provide fluid flow communication between the disinfectant solution source and the enclosure to be decontaminated.Type: GrantFiled: August 20, 2015Date of Patent: March 13, 2018Assignee: Aeroclave, LLCInventors: Ronald D. Brown, David J. Robinson, James S. Amrhein
-
Patent number: 9913924Abstract: A dispensing device for release of a volatile material includes a base, a drive arm coupled to a pendulum based drive mechanism, and a refill coupled to the drive arm. The refill includes a support base, at least one flange, a substrate coupled with the at least one flange, and a use-up cue.Type: GrantFiled: May 25, 2016Date of Patent: March 13, 2018Assignee: S. C. Johnson & Son, Inc.Inventors: Joel E. Adair, Brian T. Davis, Gregory A. Falduto, Michelle Dekea Fason, Kamran Faterioun, Donald J. Schumacher, Paulina Carlos Trevino, Katlyn Ross, Shawn Smith, Evan A. Sparks
-
Patent number: 9913925Abstract: Nonwoven (and film) topsheet and acquisition/distribution materials treated with a hydrophilic, synthetic surfactant-free finish, absorbent articles for infant or incontinence care that contain these materials, and methods for apply such finishes and/or making such absorbent articles.Type: GrantFiled: November 13, 2015Date of Patent: March 13, 2018Assignee: ATTENDS HEALTHCARE PRODUCTS, INC.Inventor: Harry J. Chmielewski
-
Patent number: 9913926Abstract: Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations and polyanions in the adhesive complex coacervate are crosslinked with one another by covalent bonds upon curing. The adhesive complex coacervates have several desirable features when compared to conventional bioadhesives, which are effective in water-based applications. The adhesive complex coacervates described herein exhibit good interfacial tension in water when applied to a substrate (i.e., they spread over the interface rather than being beaded up). Additionally, the ability of the complex coacervate to crosslink intermolecularly increases the cohesive strength of the adhesive complex coacervate.Type: GrantFiled: September 14, 2012Date of Patent: March 13, 2018Assignee: University of Utah Research FoundationInventors: Russell J. Stewart, Hui Shao
-
Patent number: 9913927Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.Type: GrantFiled: July 14, 2015Date of Patent: March 13, 2018Assignee: University of Utah Research FoundationInventor: Russell J. Stewart
-
Patent number: 9913928Abstract: The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof.Type: GrantFiled: November 14, 2014Date of Patent: March 13, 2018Assignees: GRAFTYS, UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Jean-Michel Bouler, Bruno Bujoli, Pascal Janvier, Ibrahim Khairoun, Jean-Noël Argenson
-
Patent number: 9913929Abstract: A method of preparing a bone graft. Mixing bone marrow aspirate with an effective amount of a binding reagent that is capable of binding with red blood cells in the bone marrow aspirate. The bound red blood cells are aggregated. The aggregated bound red blood cells are separated from the bone marrow aspirate to provide a supernatant. At least a portion of the supernatant is associated with an osteoconductive matrix to form the bone graft.Type: GrantFiled: October 17, 2014Date of Patent: March 13, 2018Assignee: Fortus Medical, Inc.Inventor: Robert Assell
-
Patent number: 9913930Abstract: Described herein are methods for implanting cells into a host comprising the steps of implanting into the host a device comprising a cell encapsulation chamber with at least one seal, allowing the device to vascularize, and loading the device with a human embryonic stem (hES) cell-derived pancreatic progenitor cell population.Type: GrantFiled: November 13, 2015Date of Patent: March 13, 2018Assignee: VIACYTE, INC.Inventors: Laura Martinson, Chad Green, Evert Kroon, Emmanuel Edward Baetge
-
Patent number: 9913931Abstract: A calcium phosphate monetite cement-forming composition comprises a monetite-forming calcium-based precursor powder and from 3 to 30 wt %, based on the weight of the precursor powder, of dicalcium pyrophosphate powder. Monetite cements formed form such compositions may be used in implants for correcting bone defects. Methods for bone defect repair employ implants formed from such monetite cements and slow implant resorption and/or improve in vivo bone induction in a patient.Type: GrantFiled: December 16, 2013Date of Patent: March 13, 2018Assignee: OSSDSIGN ABInventors: Jonas Åberg, Thomas Engstrand, Håkan Engqvist
-
Patent number: 9913932Abstract: The present invention relates to methods for providing polymeric composites with bone forming, such as with osteogenic and/or osteoinductive and/or osteoconductive, properties. The present invention further relates to polymeric composites provided by the present method and the use of thereof for bone implants, or grafts, specifically the use thereof for orbital floor reconstruction. Specifically, the present invention relates to methods for providing a composite with bone forming properties, the method comprises the steps of: a) providing a liquid, or liquefied, polymeric composition of homopolymers or copolymers of 1,3-trimethylene carbonate (TMC); b) adding to said liquid, or liquefied, polymeric composition one or more agents with osteogenic and/or osteoinductive and/or osteoconductive properties thereby providing a dispersion of said agents in said liquid or liquefied polymeric composition; and c) crosslinking the product obtained, thereby providing a composite with bone forming properties.Type: GrantFiled: October 26, 2011Date of Patent: March 13, 2018Assignees: UNIVERSITEIT TWENTE, RUKSUNIVERSITEIT GRONINGEN, ACADEMISCH ZIEKENHUIS GRONINGENInventors: Dirk Wybe Grijpma, Rudolf Robert Maria Bos, Anne Cornelis Van Leeuwen
-
Patent number: 9913933Abstract: In various embodiments of the present disclosure, a surgical catheter is provided. The present disclosure provides a catheter shaft that includes a distal portion and a proximal portion. The proximal portion comprises a handle operably connected to the distal portion of the elongated structure. The distal portion three radially positioned polymeric layers. At least two of the layers include chemically dissimilar polymers and at least one of the three layers includes functionalized polyvinylidene fluoride (PVDF).Type: GrantFiled: March 14, 2014Date of Patent: March 13, 2018Assignee: St. Jude Medical, Cardiology Division, Inc.Inventors: Xiaoping Guo, David P. Johnson
-
Patent number: 9913934Abstract: A radiopaque, optically translucent thermoplastic polyurethane compound is disclosed. The use of nano-sized particles of barium sulfate optionally in combination with a minor amount of certain dispersion aids allows the barium sulfate to be sufficiently dispersed within the thermoplastic polyurethane to retain optical translucency according to a defined Haze Determination Test. Medical devices, needing both visual spectrum observation before and during in-vivo medical use and radiopacity monitoring during in-vivo medical use, benefit from this compound. Optionally, a surface enhancer can also be used.Type: GrantFiled: September 8, 2014Date of Patent: March 13, 2018Assignee: PolyOne CorporationInventors: Jack Frautschi, Jing Liu, Jiannong Xu
-
Patent number: 9913935Abstract: A catheter connector assembly which may be included with a corporeal drainage system, and a method of draining fluid from a bodily cavity. The catheter connector assembly may include a catheter connector and a drainage line connector. The catheter connector may include a connector body with a coupling feature, a deformable sealing element, and a retaining member. The drainage line connector may include a drainage line body first and second hinge clips, and an actuator. The actuator is designed to deform the deformable sealing element when the drainage line connector is coupled to the catheter connector.Type: GrantFiled: March 25, 2016Date of Patent: March 13, 2018Assignee: C. R. Bard, Inc.Inventors: Mark A. Christensen, Steven M. Smith, Jim C. Beasley, Kelly B. Powers
-
Patent number: 9913936Abstract: A method for aspirating material from a patient includes providing an elongate tubular member having a lumen having a first diameter adjacent its distal end, providing an aspiration catheter including a tubular aspiration member having an aspiration lumen and configured to at least partially extend out of the lumen of the elongate tubular member, an elongate support member coupled to the tubular aspiration member, and at least one annular sealing member coupled to the tubular aspiration member and configured to seal against the first diameter, placing the distal end of the elongate tubular member into vasculature, inserting the aspiration catheter into the lumen of the elongate tubular member, extending the distal end of the tubular aspiration member out of the distal end of the elongate tubular member such that the at least one annular sealing member is aligned with the first diameter of the lumen of the elongate tubular member, and applying a vacuum to the lumen of the elongate tubular member at the such thType: GrantFiled: July 14, 2016Date of Patent: March 13, 2018Assignee: INCUVATE, LLCInventors: David M. Look, Bradley S. Culbert
-
Patent number: 9913937Abstract: Apparatus and methods are described including identifying a subject as suffering from a condition selected from the group consisting of: cardiac dysfunction, congestive heart failure, reduced renal blood flow, increased renal vascular resistance, arterial hypertension, and kidney dysfunction. In response thereto, blood pressure within a renal vein of the subject is reduced, by placing a blood pump inside the subject's renal vein and activating the impeller to pump blood from the renal vein into the subject's vena cava. Other applications are also described.Type: GrantFiled: November 3, 2015Date of Patent: March 13, 2018Assignee: MAGENTA MEDICAL LTD.Inventors: Ehud Schwammenthal, Yosi Tuval, Daniel Glozman